Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3738
+0.0038 (+1.03%)
Official Closing Price
Updated: 8:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
January 23, 2022
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry
January 19, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:
Via
Benzinga
Cybin Notes 'Milestone' Step with USPTO Notice of Allowance for CYB004
January 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi...
Via
Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance for CYB004
January 12, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004
January 12, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.
Via
Benzinga
Cybin CEO Participation in Upcoming Events Recognizes Company Expertise
January 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi...
Via
Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise
January 11, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology
January 11, 2022
Via
Investor Brand Network
Why Cybin Shares Are Rising
January 11, 2022
Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel...
Via
Benzinga
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
January 11, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise
January 10, 2022
Via
Investor Brand Network
Cybin Highlights Adelia's Milestone Achievement
January 10, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE: CYBN), a biotechnology...
Via
Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Highlights Adelia’s Milestone Achievement
January 10, 2022
Via
Investor Brand Network
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
January 09, 2022
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents.
Via
Talk Markets
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement
January 07, 2022
Via
Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
January 06, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency
January 06, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders
January 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities
January 04, 2022
Via
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance
January 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.